Mirati Therapeutics provides update on the phase III SAPPHIRE study evaluating sitravatinib in combination with Opdivo in NSCLC.

Merck Inc., known as MSD outside of the United States and Canada, announced that the European Commission (EC) has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adults.

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYLYNK-006 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, in combination with maintenance Lynparza, a PARP inhibitor, did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS) for the first-line treatment of certain patients with metastatic nonsquamous non-small cell lung cancer (NSCLC).